Bioprospecting: Uncovering Nature’s Secrets for Commercial Use

Every time you take an aspirin, use a penicillin-based antibiotic, or receive a cancer treatment derived from a plant compound, you’re benefiting from bioprospecting. Long before laboratories synthesized molecules from scratch, scientists turned to the natural world for chemical solutions. Today, that tradition continues at a global scale – and the stakes around who benefits, who’s protected, and how it’s done ethically have never been higher.

What is bioprospecting? 🔗

Bioprospecting, also known as biodiversity prospecting, is the systematic exploration of natural sources – plants, animals, fungi, and microorganisms – for biochemical compounds, genetic information, and biological structures that can be developed into commercially valuable products. These products span industries from pharmaceuticals and agriculture to cosmetics and nanotechnology.

The term blends “bio” (life) with “prospecting” (searching for resources of value), much like mineral prospectors once searched the earth for gold or coal. But unlike mining, bioprospecting doesn’t necessarily destroy what it extracts – the biological resources remain in nature while the knowledge or compound derived from them is studied and developed further.

The practice is as old as human civilization. Indigenous communities across the world identified medicinal plants, pest-repelling compounds, and fermentation processes centuries before modern science had a name for what they were doing. Estimates suggest that more than 80% of the world’s population still relies on traditional medicines derived from local plants or animals for basic health needs – a figure that underscores just how deep the connection between biodiversity and human wellbeing runs.

Industries and sectors that rely on bioprospecting 🔗

Bioprospecting is not confined to a single field. A wide range of established and emerging industries actively search biodiversity for new resources of social and commercial value.

Pharmaceuticals 🔗

This is the most prominent sector. According to research tracking FDA approvals, nearly one-third of all small-molecule drugs approved between 1981 and 2014 were either natural products or compounds derived from them. Classic examples include morphine from the opium poppy, quinine from cinchona bark for malaria, and vincristine from the Madagascar periwinkle – now a standard treatment for certain cancers. Aspirin itself was originally derived from salicin found in willow bark. More recently, artemisinin, an antimalarial compound from the plant Artemisia annua, was developed through close study of traditional Chinese medicine.

Even animal venoms have contributed to the pharmaceutical toolkit. Teprotide, isolated from the venom of the pit viper Bothrops jararaca, formed the structural basis for captopril and enalapril – two widely used cardiovascular drugs.

Biotechnology and industry 🔗

The biotechnology sector uses bioprospecting to find enzymes, proteins, and genetic sequences applicable to industrial processes. One well-known result is Taq polymerase, an enzyme discovered in heat-resistant bacteria from Yellowstone’s hot springs. This enzyme made modern DNA amplification and genetic testing possible, becoming foundational to biotechnology worldwide. Researchers also prospect for microorganisms that can break down pollutants, produce biofuels, or generate biodegradable materials – applications critical to environmental sustainability.

Agriculture 🔗

In agriculture, bioprospecting helps develop natural pesticides, biofertilizers, and crop protection tools. Bacillus thuringiensis (Bt), a soil bacterium, was discovered through bioprospecting and is now used widely as a biopesticide. Rhizobium bacteria serve as natural biofertilizers by fixing nitrogen in soil. Compounds from the neem tree have been developed into natural insecticides considered far safer than many synthetic alternatives. Resistance genes identified from wild plant species are also a growing focus, helping create crops better equipped to withstand pests and disease.

Cosmetics 🔗

Cosmetics companies increasingly turn to bioprospecting for natural actives – compounds that offer skin benefits, UV protection, or anti-aging effects. Marine organisms and extremophile microbes found in harsh environments are particularly interesting to this sector because they produce unique compounds not found elsewhere in nature.

The three processes of bioprospecting 🔗

Bioprospecting operates through three distinct approaches: chemical prospecting, gene prospecting, and bionic prospecting. Each targets different types of biological value.

Chemical prospecting 🔗

This is the most traditional approach. It involves collecting biological samples – from plants, fungi, marine organisms, or microbes – and analyzing them for active chemical compounds. Scientists screen these extracts against biological targets, looking for antibiotic, antifungal, anticancer, or other therapeutic activity. The biodiversity-driven method involves mass sampling across large numbers of organisms without prior knowledge of where useful compounds might be found. A more targeted approach draws on chemotaxonomic knowledge (understanding which chemical families appear in which organism groups) or ethnobotanical knowledge – what indigenous communities have used historically – to narrow the search considerably.

Studies show that biodiversity prospecting is significantly more efficient when guided by indigenous knowledge. One analysis found that 86% of plants used by Samoan healers showed significant biological activity when tested in a laboratory – a hit rate far higher than random screening.

Gene prospecting 🔗

Gene prospecting focuses not on chemical compounds but on genetic material. Scientists search for specific genes or gene clusters that encode useful proteins, enzymes, or metabolic pathways. With advances in next-generation sequencing (NGS) and metagenomics, it is now possible to sequence the genetic material of entire microbial communities from environmental samples – soil, ocean water, or even cave ecosystems – without needing to isolate individual organisms in the lab. This dramatically expands the scope of gene prospecting and opens access to organisms that are difficult or impossible to culture conventionally. Once a target gene is identified, it can be transferred into a host organism like E. coli to produce the desired protein or compound at scale.

Bionic prospecting 🔗

Bionic prospecting is the newest of the three approaches. Rather than extracting compounds or genes, it focuses on understanding the physical structures, mechanisms, and designs that organisms have evolved – then mimicking them for engineering purposes. New sensor technologies, architectural designs, and materials science innovations are emerging from this field. The structure of a butterfly wing, the aerodynamics of a bird, or the adhesive properties of a gecko’s foot have all inspired engineering breakthroughs. Bionic prospecting treats biodiversity as a design library built over millions of years of evolution.

Benefits of bioprospecting 🔗

The case for bioprospecting rests on both scientific and economic grounds.

The most direct benefit is the discovery of life-saving medicines and agricultural tools. Tropical forests alone may hold over 300 undiscovered drugs, and researchers estimate the potential anticancer value of marine biodiversity alone could reach trillions of dollars. Bioprospecting also provides a compelling economic argument for biodiversity conservation – if a rainforest holds commercially valuable compounds, there is a tangible financial incentive to protect it.

Benefit-sharing frameworks, when properly implemented, can also support local economies. The 1992 Convention on Biological Diversity (CBD) established that nations have sovereign rights over their genetic resources and that access must come with fair and equitable sharing of benefits. An early and well-studied example was a deal between pharmaceutical giant Merck and Costa Rica’s Instituto Nacional de Biodiversidad (INBio), where Merck paid $1 million upfront for sample collection rights and committed to royalty payments on any resulting products.

Challenges: legal, ethical, and ecological 🔗

Despite its potential, bioprospecting is not without serious problems.

Biopiracy and indigenous rights 🔗

The most contentious issue is biopiracy – the use of biological resources or indigenous knowledge without the authorization or fair compensation of the source communities. When pharmaceutical companies patent products derived from traditional knowledge that indigenous peoples have held for generations, those communities typically receive nothing. The 1992 Convention on Biological Diversity shifted the framing of biological resources from a shared global heritage to sovereign national property – but enforcement remains inconsistent, and indigenous communities often lack the legal expertise or resources to assert their rights under these frameworks.

Conservation risks 🔗

Bioprospecting can lead to overharvesting of target species if commercial demand outpaces what ecosystems can sustain. Marine organisms like cone shells, harvested for neuropharmaceutical research, have faced pressure in certain areas. Responsible bioprospecting programs are now expected to include ecological assessments and avoid dependency on geographically restricted or ecologically fragile populations.

Legal and intellectual property complexity 🔗

The legal landscape around bioprospecting is genuinely complex. The Nagoya Protocol, which came into force in 2014 as an extension of the CBD, provides a more specific framework for access and benefit-sharing, requiring prior informed consent from source countries before biological resources are collected. However, the protocol has not been ratified universally, and the gap between what the law requires and what actually happens on the ground remains wide in many biodiversity-rich regions.

Commercial viability barriers 🔗

Drug development is expensive and slow. The financial risk involved means that much of today’s bioprospecting happens in academic institutions rather than large pharmaceutical companies, which largely retreated from natural products research in the 1990s in favor of combinatorial chemistry. Even when a promising compound is found, there may not be enough of the source material to synthesize it at scale, or the legal negotiations over intellectual property rights may stall development entirely.

The path forward 🔗

Bioprospecting sits at an intersection that is both scientifically exciting and ethically demanding. As antimicrobial resistance grows and demand for novel medicines increases, the pressure to explore biodiversity more systematically will only intensify. The tools available – metagenomics, high-throughput screening, AI-assisted compound identification – are more powerful than ever. But the framework around who can prospect, under what conditions, and who shares in the rewards is still catching up.

Done responsibly, bioprospecting can simultaneously advance medicine, support conservation, and provide economic benefits to biodiversity-rich nations. Done carelessly, it reproduces old patterns of extraction and inequity under a scientific label. The difference lies almost entirely in governance, transparency, and the genuine inclusion of indigenous communities in decisions that directly affect their knowledge and lands.

What do you think? If a pharmaceutical company discovers a blockbuster drug using knowledge held by an indigenous community for centuries, what would a truly fair compensation arrangement look like? And should countries that have not ratified the Nagoya Protocol still be bound by its benefit-sharing principles?

References

1. https://en.wikipedia.org/wiki/Bioprospecting
2. https://www.ebsco.com/research-starters/health-and-medicine/genetic-prospecting
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3380369/
4. https://www.thepharmajournal.com/archives/2019/vol8issue4/PartE/8-2-52-342.pdf
5. https://www.sciencedirect.com/topics/medicine-and-dentistry/bioprospecting
6. https://www.researchgate.net/publication/264238213_Bioprospecting
7. https://www.omicsonline.org/open-access/biodiversity-bioprospecting-traditional-knowledge-sustainable-development-and-value-added-products-a-review-2573-4555-1000256-97536.html
8. https://www.mdpi.com/2079-6382/9/5/229
9. https://link.springer.com/chapter/10.1007/978-3-031-24823-8_14
10. https://novotech-cro.com/faq/bioprospecting-and-biopiracy
11. https://www.ebsco.com/research-starters/science/biopiracy-and-bioprospecting
12. https://www.pharmaceutical-technology.com/features/featurenature-provides-bioprospecting-for-new-blockbuster-drugs-4867033/